PCT semi-Quantitative Rapid Test Device

The PCT-Quantitative Rapid Test Device (Whole Blood/Serum/Plasma) is used for semi-quantitative determination and monitoring of PCT concentrations in whole blood/serum/plasma specimens.

The Patent Cooperation Treaty (PCT) assists applicants in seeking patent protection internationally for their inventions, helps patent Offices with their patent granting decisions, and facilitates public access to a wealth of technical information relating to those inventions. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in 148 countries throughout the world.

The PCT-Quantitative Rapid Test Device (Whole Blood/Serum/Plasma) detects Patent Cooperation Treaty through visual interpretation of color development on the internal strip. Anti-PCT antibodies are immobilized on the test region of the membrane. During testing, the specimen reacts with anti-PCT antibodies conjugated to colored particles and precoated on the sample pad of the test. The mixture then migrates through the membrane by capillary action, and interacts with reagents on the membrane. If the intensity of the test band is weaker than reference band 2 (R2), it indicates that the PCT level in the specimen is between 0.5-2.0ng/ml. If the intensity of the test band is weaker than reference band 1 (R1) but stronger than reference band 2 (R2), it indicates that the PCT level in the specimen is between 2.0-10.0 ng/ml. If the intensity of the test band (T) is stronger than the reference band (R1), it indicates that the PCT level is above 10.0 ng/ml. The appearance of control line serves as a procedural control, indicating that the proper volume of specimen has been added and membrane wicking has occurred.

SUPPLIER:SPAN BIOTECH LTD.

Welcome to your inquiries!